Mre11-Rad50-Nbs1 (MRN)-ATM pathway inhibitor that blocks the 3' and 5' exonuclease activity associated with Mre11. Mirin prevents ATM activation in response to double strand breaks (IC50 = 12 μM) and induces G2 cell cycle arrest. Mirin also blocks homology-directed repair in vitro.
BMC Biol. 2021 May 20;19(1):108.
Very long intergenic non-coding (vlinc) RNAs directly regulate multiple genes in cis and trans
Mirin purchased from AbMole
Sci Rep. 2020 Feb 4;10(1):1794.
A CRISPR/Cas13-based Approach Demonstrates Biological Relevance of Vlinc Class of Long Non-Coding RNAs in Anticancer Drug Response
Mirin purchased from AbMole
| Molecular Weight | 220.25 |
| Formula | C10H8N2O2S |
| CAS Number | 1198097-97-0 |
| Solubility (25°C) | DMSO 24 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related ATM/ATR Products |
|---|
| Tuvusertib
Tuvusertib is a selective and orally active ATR inhibitor that kills tumor cells by preventing the repair of damaged DNA with a Ki value below 1 μΜ. |
| ATR-IN-24
ATR-IN-24 is a ATR inhibitor. |
| ATM Inhibitor-6
ATM inhibitor-6 (A-193) is a selective ATM kinase inhibitor. |
| ATR-IN-21
ATR-IN-21 is a potent ATR inhibitor with an IC50 value of <1000 nM. |
| ATR-IN-23
ATR-IN-23 is a potent and selective ATR inhibitor with an IC50 of 1.5 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
